New stem cell particle injection could soothe severe eczema
NCT ID NCT06055361
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tests an experimental injection called BxC-I17e, made from stem cell particles, in 45 adults with moderate to severe eczema (atopic dermatitis) who haven't responded well to standard creams. The main goal is to check safety and tolerability, with a small look at whether it helps symptoms. It's a first step to see if this approach is worth studying further.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BxC-I17e (a cell-based injection made from stem cell particles)
What this could lead to
If safe and effective, this could point toward a new treatment option for moderate to severe eczema that is easier to manage.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not proof of effectiveness. The treatment may not work or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Arkansas Research Trials
RECRUITINGNorth Little Rock, Arkansas, 72117, United States
Contact
-
DermDox Centers for Dermatology
RECRUITINGCamp Hill, Pennsylvania, 17011, United States
Contact
-
University of Pennsylvania
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact